. Author manuscript; available in PMC: 2019 Oct 1.

Published in final edited form as: Clin Trials. 2018 Jul 23;15(5):489–498. doi: 10.1177/1740774518789098

Table 2.

Results of Cox-type regression (stratified by fms-related tyrosine kinase 3 gene status) evaluating the effect of midostaurin versus placebo on multi-state transitions

Transition	Number at risk	Number events	Hazard ratio^a	95% Confidence interval of the hazard ratio	P-value
Entry to remission	717	504	1.180	[0.99–1.41]	0.064
Entry to death	717	137	1.110	[0.79–1.56]	0.546
Remission to relapse	504	231	0.769	[0.59–1]	0.046
Remission to death	504	53	0.554	[0.32–0.96]	0.034
Relapse to death	231	168	0.968	[0.71–1.32]	0.838

Hazard ratio of midostaurin compared to placebo for the given transition